I am grateful to colleagues in all parties who have supported the motion in my name and I welcome the opportunity to open today’s debate on European antibiotic awareness day, which took place in November last year, and to pay tribute to the valuable work undertaken by the Royal Pharmaceutical Society in raising awareness of the issue of antimicrobial resistance. The issue is important not just for individuals but for healthcare professionals and society as a whole, presenting, as it does, a major global health challenge.
Antimicrobial medicines include antibiotics and antifungal and antiviral treatments. Resistance arises through naturally occurring mutations. Overuse and misuse of antibiotics is thought to be a major cause of resistance, and that is facilitated in many countries by their availability to be bought over the counter without prescription. However, even where that is not the case, as in the United Kingdom, prescribing practices vary immensely.
Not completing antibiotics courses and prescribing doses that are too low, or prescribing for too short a period of time, allow stronger and more virulent bacteria to flourish and encourage the development of resistance. Resistance to antifungal and antiviral medicines is now also beginning to appear.
None of us should be in any doubt about the scale of the problem. The global impact of antibiotic resistance must not be underestimated; its effect on human health has been compared to the effect of climate change on human health. The emergence of infections that are resistant to drug treatment is a growing public health problem. If antibiotics are not used responsibly, we could face a situation in the future in which we simply do not have effective cures for infections.
In April 2014, the World Health Organization stated:
“Without urgent, coordinated action by many stakeholders, the world is headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill”.
That is the scale of the problem that we face.
Across the European Union, 25,000 people a year die from infections that are caused by multidrug-resistant bacteria. It has been estimated that, by 2050, antimicrobial resistance will affect 10 million more people annually worldwide.
The inappropriate use of antibiotics can have serious public health risks. Antibiotics can disrupt the natural intestinal bacteria that we all have and allow organisms such as Clostridium difficile to flourish, with potentially severe consequences for patients.
Without effective antibiotics, many routine treatments will become increasingly dangerous. Setting broken bones, basic operations and even chemotherapy rely on access to antibiotics that work, and many procedures that currently allow people to live active lives for longer, such as hip operations, might become too risky to undertake. Organ transplantation would be severely compromised without the ability to treat secondary infections.
The World Health Organization estimates that the average human lifespan is extended by 20 years through the use of antimicrobials. Between 2000 and 2010, the global consumption of antibiotics in human medicine rose by nearly 40 per cent. Over the past 30 years, a new infectious disease has been discovered almost every year, whereas only two new classes of antibiotics have been introduced.
For a variety of reasons, antimicrobials are difficult to develop. Potential treatments can be difficult to formulate as medicines and can be expensive because of the cost of individual clinical trials for each therapeutic area in which the antimicrobial will be used. Furthermore, there is little incentive for pharmaceutical companies to develop medicines that are used for only short periods of time to treat and cure infections.
In November last year, I was pleased to host a seminar in Parliament on behalf of the Royal Pharmaceutical Society in which the Scottish Government’s healthcare associated infection medical adviser, Professor Alistair Leonard, outlined the Scottish Government’s strategic objectives in the area. They are to improve the knowledge and understanding of antimicrobial resistance; to conserve the effectiveness of existing treatments; and to stimulate the development of new antibiotics, diagnostics and novel therapies.
The Royal Pharmaceutical Society recently published a scientific guide entitled “New Medicines, Better Medicines, Better Use of Medicines”, which recommends educating the public and patients on the use of antibiotics and their place in therapy; encouraging further development of antimicrobial stewardship by healthcare professionals to maintain the effectiveness of current and any future antimicrobials; and supporting the discovery and development of new antimicrobials or treatment methods by developing new financial incentives.
Antimicrobial stewardship means prescribing appropriately and conserving the antibiotics that we currently have using the evidence-based guidelines that have been developed by specialist teams. Only today, the recommendations of the review on antimicrobial resistance, which was chaired by the economist Jim O’Neill, were published in “Tackling a global health crisis: initial steps”. That United Kingdom-wide initiative has attracted a range of clinical and technical input, including from Professor Mark Woolhouse, who is professor of infectious disease epidemiology at the University of Edinburgh. Among the recommendations are the setting up of a global innovation fund of around $2 billion and the training of a new generation of scientists in that field of study.
New approaches to developing antimicrobials are urgently required to make that more attractive and to promote innovative research, such as on therapies to boost immune systems and on using specific viruses that kill bacteria without producing resistance or damaging human cells. Scotland is well placed to encourage that type of research and to work with industry to develop better and safer medicines through innovative research.
We must reduce prescribing to the lowest and safest levels. I am thinking of the need to minimise the overuse of broad-spectrum antibiotics. In secondary care, prescribers should review prescriptions daily and should consider whether antibiotics can be safely stopped or changed from a broad-spectrum antibiotic to a narrow-spectrum antibiotic, which has less potential to allow resistant Clostridium difficile infections to develop, thus improving patient safety in hospitals.
Success depends on sustainable change. More awareness is needed among patients and the public about the seriousness of the challenges that we face if we are not to return to an era in which infections are untreatable.
All healthcare professionals must work in partnership with their patients to discuss when antibiotics are necessary and when they are not required. Healthcare professionals are ideally placed to point out the alternatives that may be available, and pharmacists have a specific role to play in that regard. Specialist pharmacists play a leading role in stewardship to ensure the appropriate prescribing of antibiotics as part of a multidisciplinary approach through the Scottish antimicrobial prescribing group. Much has already been achieved by antimicrobial pharmacists, working with national health service board antimicrobial management teams, to influence hospital prescribing.
The Scottish Government, Healthcare Improvement Scotland, Community Pharmacy Scotland and the Royal Pharmaceutical Society supported European antibiotic awareness day with a resource pack comprising a poster, patient information leaflets and self-care information sheets, which were distributed to all community pharmacies in Scotland. In addition, a self-care guide from the Royal College of General Practitioners has now been adapted for use by community pharmacies. The guide is designed to manage patients’ expectations of illness duration and highlights potentially serious symptoms that warrant further review.
Only through Governments, academic research communities, pharmaceutical companies and other stakeholders working together in Scotland, across the UK and internationally will we raise awareness of this important issue and develop the new funding models that are necessary to incentivise the development and appropriate use of new antibiotics. In doing so, we will be saving and improving the lives of millions of people, not just here in Scotland but across the world. What better endeavour could there be than that?
12:42